Home
About
Overview
Sharing Data
ORCID
Help
History (149)
Picomolar to Micromolar: Elucidating the Role of Distal Mutations in HIV-1 Protease in Conferring Drug Resistance.
Evaluating the Role of HLA-DM in MHC Class II-Peptide Association Reactions.
Comparative Analysis of Decompression Versus Decompression and Fusion for Surgical Management of Lumbar Spondylolisthesis.
Jaw Abnormalities
Subcutaneous versus intravenous daratumumab in multiple myeloma - Authors' reply.
See All 149 Pages
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Subcutaneous versus intravenous daratumumab in multiple myeloma - Authors' reply.
Mateos MV, Usmani SZ. Subcutaneous versus intravenous daratumumab in multiple myeloma - Authors' reply. Lancet Haematol. 2020 08; 7(8):e559.
View in:
PubMed
subject areas
Administration, Intravenous
Antibodies, Monoclonal
Humans
Multiple Myeloma
authors with profiles
Saad Usmani MD